

administering to said patient a therapeutically effective amount of a pharmaceutical composition comprising a polypeptide having an amino acid sequence as shown in SEQ ID NO:1.

B1
Cont
102. The method of claim 101, wherein said hematological disorder involves myeloid progenitor cells.

103. The method of claim 102, wherein said myeloid progenitor cell is a CD34⁺ cell. --

REMARKS

The foregoing amendments to the claims are fully supported in the specification as originally filed. Accordingly, the foregoing amendments to the claims do not add new matter; their entry is therefore respectfully requested.

Applicants believe that the present application is now in condition for examination. If the Examiner believes, for any reason, that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at the number provided.

Prompt and favorable consideration of the foregoing amendments, and entry of the same into the present application, are respectfully requested.

It is not believed that extensions of time or fees for net addition of claims are required, beyond those that may otherwise be provided for in documents accompanying this paper. However, in the event that additional extensions of time are necessary to allow consideration of this paper, such extensions are hereby petitioned under 37 CFR § 1.136(a), and any fee required therefore (including fees for net addition of claims) is hereby authorized to be charged to Deposit Account No. 16-0605.